Register now
Login
OCTOBER 15-16, 2026
Fondazione Cariplo - Conference Center
MILAN, ITALY
Scientific Program | Delta Cure - 5th International Meeting |...
On this page you will find the Scientific Program of the Delta...
Scientific Program
| 11.00-11.15 | Welcome by the Chairs P. Lampertico and H. Wedemeyer |
| SESSION 1 | Bookmarks and Epidemiology Chairs: S. Hamid and O. Lesi |
| 11.15-11.30 | Bookmarks in HDV: a 2025/2026 overview L. Sandmann |
| 11.30-11.45 | Epidemiology of HDV in Low to Middle IC: WHO perspectives O. Lesi |
| 11.45-12.00 | Epidemiology of HDV in US: still a black box? R. Wong |
| 12.00-12.10 | ORAL PRESENTATION 1High prevalence of HDV and HBV detected amongst household contacts of HDV positive individuals in rural Sindh S.S. Hamid |
| 12.10-12.45 | Panel discussion Chairs and Speakers |
| 12.45-13.45 | Lunch |
| SESSION 2 | Pathophysiology: Virology and Immunology Chairs: M.R. Brunetto and S. Urban |
| 13.45-14.00 | Virology update J. Lucifora |
| 14.00-14.15 | Immunology update: what can we learn from liver spatial transcriptomics? M. Locatelli |
| 14.15-14.25 | ORAL PRESENTATION 2Paired liver and serum deep sequencing reveals differences between circulating HDV and intrahepatic viral populations J. Ringlander |
| 14.25-14.35 | ORAL PRESENTATION 3Identification of GBP3 as a novel host factor required for Hepatitis Delta Virus recognition by hepatocytes R. Fouille |
| 14.35-14.50 | Poster summaries 1 L. Allweiss |
| 14.50-15.20 | Panel discussion Chairs, Speakers and H. Kefalakes |
| 15.20-16.20 | Coffee break and Poster Session No. 1 with guided Poster Tour M. Sonneveld and C. Stern |
| SESSION 3 | Diagnostics and Natural History Chairs: K. Agarwal and M. Dandri |
| 16.20-16.35 | Diagnostics update M.P. Anolli |
| 16.35-16.50 | HCC in HDV patients: pathogenesis, incidence and predictors G. Papatheodoridis |
| 16.50-17.00 | ORAL PRESENTATION 4Quantitative anti-HDV measurement as a diagnostic surrogate of HDV replication E. Dileo |
| 17.00-17.10 | ORAL PRESENTATION 5 Predictors of advanced chronic liver disease (ACLD) in patients with Hepatitis Delta Virus (HDV) infection: does the genotype matter? M. Cardoso |
| 17.10-17.25 | Poster summaries 2 I. Carey |
| 17.25-17.55 | Panel discussion Chairs, Speakers and M. Levrero |
| 17.55-19.00 | Presentation of Delta Cure 2026 Awardee Chairs: P. Lampertico and H. Wedemeyer |
| Distinguished Lecture C. Sureau | |
| 19.00-19.05 | Day 1 closing P. Lampertico and H. Wedemeyer |
| SESSION 4 | Current treatment options Chairs: R. Esteban and L. Gheorghe |
| 08.30-08.45 | BLV in clinical trials: filling the gaps (a debate) M. Buti and N. Reau |
| 08.45-09.00 | Long-term outcomes in BLV-treated patients E. Degasperi |
| 09.00-09.10 | ORAL PRESENTATION 6 Clinical and economic value of early treatment with bulevirtide in chronic Hepatitis Delta Virus R. Dominguez |
| 09.10-09.20 | ORAL PRESENTATION 7 Hepatic recompensation according to Baveno VII in decompensated chronic Hepatitis Delta treated with bulevirtide: a multicenter experience M. Meszaros |
| 09.20-09.30 | ORAL PRESENTATION 8 Predicting time to cure in HDV patients treated with bulevirtide and pegylated interferon-alpha in the SEE-D trial H. Dahari |
| 09.30-09.45 | Poster summaries 3 M. Jachs |
| 09.45-10.15 | Panel discussion Chairs and Speakers |
| 10.15-11.15 | Coffee break and Poster Session No. 2 with guided Poster Tour M. Cardoso and G.P. Caviglia |
| SESSION 5 | Treatment options in clinical development Chairs: T. Asselah and S. Lens |
| 11.15-11.30 | Anti-HBs monotherapies: results of phase II/III studies T. Kushner |
| 11.30-11.45 | Anti-HBs and siRNA combination: results of phase II/III studies P. Kennedy |
| 11.45-12.00 | Other therapeutic approaches for HDV in phase I/II S. Aleman |
| 12.00-12.10 | ORAL PRESENTATION 9 Histologic improvement and reduction in necroinflammation with lonafarnib-based therapy in chronic Hepatitis Delta: phase 3 D-LIVR trial N. Reau |
| 12.10-12.20 | ORAL PRESENTATION 10 The efficacy and safety of siRNA ozisiran in patients with chronic Hepatitis D: Interim results through treatment Week 36 from the phase 2a RC04T001 trial K. Lindahl |
| 12.20-12.35 | ASO-based phase III studies in HBV: any relevance for HDV? N. Terrault |
| 12.35-13.05 | Panel Discussion Chairs, Speakers, O. Etzion and B. Testoni |
| 13.05-14.00 | Lunch |
| SESSION 6 | Unmet needs in Hepatitis Delta Chairs: C. Coffin and T. Reiberger |
| 14.00-14.15 | BAVENO VIII update: any change for HDV patients? A. Berzigotti |
| 14.15-14.30 | Liver transplantation for HDV: time for HBIG-free regimens? P. Burra |
| 14.30-14.45 | The impact of MASH/MASLD in HBV and HDV: metHBV and metHDV? Z. Younossi |
| 14.45-15.15 | Panel discussion Chairs, Speakers and A.M. Aghemo |
| 15.15-15.50 | Roundtable discussion Chairs: P. Lampertico and H. Wedemeyer Academia, Pharma, Diagnostics, Patient Associations |
| 15.50-16.00 | Closing Remarks and farewell P. Lampertico and H. Wedemeyer |
